Literature DB >> 15499118

Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.

R S Taylor1, M F Drummond, G Salkeld, S D Sullivan.   

Abstract

Mesh：

Year:  2004        PMID： 15499118      PMCID： PMC524116          DOI： 10.1136/bmj.329.7472.972

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.

Authors:  S R Hill; A S Mitchell; D A Henry
Journal:  JAMA       Date:  2000-04-26       Impact factor: 56.272

2.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

Review 3.  Theory versus practice: a review of 'willingness-to-pay' in health and health care.

Authors:  J A Olsen; R D Smith
Journal:  Health Econ       Date:  2001-01       Impact factor: 3.046

Review 4.  Health economic guidelines--similarities, differences and some implications.

Authors:  J Hjelmgren; F Berggren; F Andersson
Journal:  Value Health       Date:  2001 May-Jun       Impact factor: 5.725

Review 5.  NICE: faster access to modern treatments? Analysis of guidance on health technologies.

Authors:  J Raftery
Journal:  BMJ       Date:  2001-12-01

6.  Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).

Authors:  B George; A Harris; A Mitchell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach.

Authors:  D B Mather; S D Sullivan; D Augenstein; D S Fullerton; D Atherly
Journal:  Am J Manag Care       Date:  1999-03       Impact factor: 2.229

8.  Is the NICE process flawed?

Authors:  I Benjamin; G Poston; D Sherlock
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

9.  After Nice: where now for health policy in the European Union?

Authors:  Martin McKee; Laura Maclehose; Elias Mossialos
Journal:  J R Soc Med       Date:  2003-01       Impact factor: 5.344

10.  Health economic evaluation in Japan: a case study of one aspect of health technology assessment.

Authors:  Adam Oliver
Journal:  Health Policy       Date:  2003-02       Impact factor: 2.980
View more
  40 in total

1.  Modelling lifetime QALYs and health care costs from different drinking patterns over time: a Markov model.

Authors:  Carolina Barbosa; Benjamin Taylor; Christine Godfrey; Juergen Rehm; Steve Parrott; Colin Drummond
Journal:  Int J Methods Psychiatr Res       Date:  2010-06       Impact factor: 4.035

2.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 3.  Role of pharmacoeconomic analysis in R&D decision making: when, where, how?

Authors:  Paul Miller
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Economic evaluations: a new avenue of outcome assessment in spinal disorders.

Authors:  Nicole van der Roer; Norbert Boos; Maurits W van Tulder
Journal:  Eur Spine J       Date:  2005-12-01       Impact factor: 3.134

Review 5.  Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; David J Torgerson
Journal:  Osteoporos Int       Date:  2005-06-25       Impact factor: 4.507

Review 6.  The cost-effectiveness of drug-eluting stents: a systematic review.

Authors:  Suzanne Ligthart; Floortje Vlemmix; Nandini Dendukuri; James M Brophy
Journal:  CMAJ       Date:  2006-12-19       Impact factor: 8.262

7.  Do drugs reduce utilisation of other healthcare resources?

Authors:  Pierre-Yves Crémieux; Pierre Ouellette; Patrick Petit
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

8.  The new myth: the social value of the QALY.

Authors:  Werner Brouwer; Job van Exel; Rachel Baker; Cam Donaldson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes.

Authors:  D Ross Camidge; James J Oliver; Carolyn Skinner; Ben Attwood; Fiona Nussey; Duncan Jodrell; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

10.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.